For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Xiaojun Wu, Tong Wang, Yilu Zhou, Xiaofan Liu, Hong Zhou, Yang Lu, Weijun Tan, Mingli Yuan, Xuhong Ding, Jinjing Zou, Ruiyun Li, Hailing Liu, Rob M. Ewing, Yi Hu, Hanxiang Nie, Yihua Wang. Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes [J].VIROLOGICA SINICA, 2020, 35(6) : 853-856.  http://dx.doi.org/10.1007/s12250-020-00296-1

Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes

  • Corresponding author: Yi Hu, huyi_pub@163.com, ORCID: http://orcid.org/0000-0002-2882-5210
    Hanxiang Nie, nhxbj@sohu.com, ORCID: http://orcid.org/0000-0002-7482-9474
    Yihua Wang, yihua.wang@soton.ac.uk, ORCID: http://orcid.org/0000-0001-5561-0648
  • Received Date: 09 July 2020
    Accepted Date: 31 August 2020
    Published Date: 30 September 2020
    Available online: 01 December 2020
  • We reported recently that hypertension is a risk factor for severe cases of COVID-19, independent of age and other variables (Liu et al. 2020a). An important question is why patients with hypertension and diabetes yield poorer clinical outcomes than those without. Human pathogenic coronavirus SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for viral cell entry. Since the levels of ACE2 are substantially increased in patients with hypertension or diabetes, who are treated with ACE inhibitors (ACEIs) and angiotensin Ⅱ type-Ⅰ receptor blockers (ARBs) (Ferrario et al. 2005), Fang and colleagues hypothesized that ACE2-stimulating drugs could potentially increase the risk of developing severe COVID-19 (Fang et al. 2020). This was not supported by a recent study led by Dr. Reynolds (Reynolds et al. 2020), whose analysis showed no positive association for ACEIs or ARBs for either the risk of SARS-CoV-2 infection or severe illness (Reynolds et al. 2020). What else might explain the poorer clinical outcomes of COVID-19 patients with hypertension or diabetes?To explore this question, we re-analysed the same cohort of 99 COVID-19 patients discharged from the general wards of Renmin Hospital of Wuhan University between 5 February 2020 and 14 March 2020 (Ethics approval No: WDRY2020-K124) (Liu et al. 2020a, b).

  • 加载中
    1. Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for covid-19 infection? Lancet Respir Med 8:e21
        doi: 10.1016/S2213-2600(20)30116-8

    2. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin ii receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111:2605–2610
        doi: 10.1161/CIRCULATIONAHA.104.510461

    3. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical Treatment Expert Group for C (2020a) Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis. Eur Respir J 55:2000547
        doi: 10.1183/13993003.00547-2020

    4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C (2020b) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720
        doi: 10.1056/NEJMoa2002032

    5. Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, Tan W, Yuan M, Ding X, Zou J, Li R, Liu H, Ewing RM, Hu Y, Nie H, Wang Y (2020a) Risk factors associated with disease severity and length of hospital stay in covid-19 patients. J Infect 81:e95–e97
        doi: 10.1016/j.jinf.2020.04.008

    6. Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, Tan W, Yuan M, Ding X, Zou J, Li R, Liu H, Ewing RM, Hu Y, Nie H, Wang Y (2020b) Temporal radiographic changes in covid-19 patients: relationship to disease severity and viral clearance. Sci Rep 10:10263
        doi: 10.1038/s41598-020-66895-w

    7. Lopez Gelston CA, Mitchell BM (2017) Recent advances in immunity and hypertension. Am J Hypertens 30:643–652
        doi: 10.1093/ajh/hpx011

    8. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS (2020) Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med 382:2441–2448
        doi: 10.1056/NEJMoa2008975

    9. Yuan M, Yin W, Tao Z, Tan W, Hu Y (2020) Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in wuhan, China. PLoS ONE 15:e0230548
        doi: 10.1371/journal.pone.0230548

    10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, China: a retrospective cohort study. Lancet 395:1054–1062
        doi: 10.1016/S0140-6736(20)30566-3

    11. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang BH, Li H (2020) Association of blood glucose control and outcomes in patients with covid-19 and pre-existing type 2 diabetes. Cell Metab 395:1054–1062

    12. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) Sars-cov-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179
        doi: 10.1056/NEJMc2001737

  • 加载中

Figures(1) / Tables(1)

Article Metrics

Article views(4604) PDF downloads(11) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes

      Corresponding author: Yi Hu, huyi_pub@163.com
      Corresponding author: Hanxiang Nie, nhxbj@sohu.com
      Corresponding author: Yihua Wang, yihua.wang@soton.ac.uk
    • 1. Department of Respiratory and Critical Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China
    • 2. Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton SO17 1BJ, UK
    • 3. Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK
    • 4. Department of Pulmonary and Critical Care Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
    • 5. NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton SO16 6YD, UK

    Abstract: We reported recently that hypertension is a risk factor for severe cases of COVID-19, independent of age and other variables (Liu et al. 2020a). An important question is why patients with hypertension and diabetes yield poorer clinical outcomes than those without. Human pathogenic coronavirus SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for viral cell entry. Since the levels of ACE2 are substantially increased in patients with hypertension or diabetes, who are treated with ACE inhibitors (ACEIs) and angiotensin Ⅱ type-Ⅰ receptor blockers (ARBs) (Ferrario et al. 2005), Fang and colleagues hypothesized that ACE2-stimulating drugs could potentially increase the risk of developing severe COVID-19 (Fang et al. 2020). This was not supported by a recent study led by Dr. Reynolds (Reynolds et al. 2020), whose analysis showed no positive association for ACEIs or ARBs for either the risk of SARS-CoV-2 infection or severe illness (Reynolds et al. 2020). What else might explain the poorer clinical outcomes of COVID-19 patients with hypertension or diabetes?To explore this question, we re-analysed the same cohort of 99 COVID-19 patients discharged from the general wards of Renmin Hospital of Wuhan University between 5 February 2020 and 14 March 2020 (Ethics approval No: WDRY2020-K124) (Liu et al. 2020a, b).